The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An investigator-initiated monocentric phase I dose escalation trial of temsirolimus and irinotecan (TEMIR) in patients with relapsing glioblastoma multiforme (reGBM).
Max E. Scheulen
No relevant relationships to disclose
Heike Richly
No relevant relationships to disclose
Halime Kalkavan
No relevant relationships to disclose
Andreas-Claudius Hoffmann
No relevant relationships to disclose
Isabel Virchow
No relevant relationships to disclose
Ralf A. Hilger
No relevant relationships to disclose
Susanne Koeppen
No relevant relationships to disclose
Ulrich Sure
No relevant relationships to disclose
Martin H. Schuler
Consultant or Advisory Role - Pfizer
Joerg Hense
No relevant relationships to disclose